Review maps peptide-drug conjugate targets and hurdles in breast cancer

The wire

1. 01A review in the Journal of Pharmacology and Experimental Therapeutics surveys peptide-drug conjugate design for breast cancer, covering emerging receptor targets, linker strategies and payload selection.
2. 02The authors argue PDCs offer better tumor penetration and lower immunogenicity than antibody-drug conjugates, a modality shift relevant to anyone tracking peptide therapeutics beyond metabolic disease.
3. 03Proposed fixes include peptide modification, nanocarrier integration and structural optimization; this is a narrative review, not new data, and no PDC results are reported.

From the source

Peptide-drug conjugates in breast cancer therapy: Emerging targets, translational challenges, and optimization strategies

The Journal of pharmacology and experimental therapeutics · 2026 Jul 31 · Zhang H, Wei X, Wang J et al.